Please try another search
Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. It operates in Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Boshutai, a small molecule drug to treat diabetes. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agent for the treatment of Type 2 diabetes. The company was incorporated in 2001 and is headquartered in Sha Tin, Hong Kong.
Name | Age | Since | Title |
---|---|---|---|
Zhi Gang Zhao | 58 | 2014 | CEO & Executive Director |
Kingsley Leung | 36 | 2014 | Executive Chairman of the Board |
Dawei Chen | 53 | 2017 | Executive Vice Chairman of the Board |
Kai Ming Chow | 57 | 2016 | Independent Non-Executive Director |
Qimin Ren | 68 | 2017 | Independent Non-Executive Director |
Kwok Wing Yau | 47 | 2019 | Non-Executive Director |
Qingshan Ma | 44 | 2019 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review